Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale. This will allow comparison with previous studies which have only used inhalation of the drug as a vapour.
A Randomised, Double-blind, Placebo-controlled, Dose Ascending Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled GSK159797 Delivered by Dry Powder Inhaler in Mild to Moderate Asthmatic Subjects
Study Start Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Safety and tolerability including blood test results, effects on the heart, pulse rate and blood pressure, and side effects.
Secondary Outcome Measures :
Effects on the lung at 12 and 24hrs Effects on the heart, blood pressure and pulse rate at 8hrs Changes in the amount of glucose and potassium in the blood 4 and 8hrs Amount of drug in the body (blood and urine).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects with mild to moderate stable asthma but no other lung problems.
Male subjects or females who are not able to get pregnant (e.g. post-menopausal or surgically sterile).
Subjects that show a measurable improvement in the function of their lungs after a single dose of salbutamol.
Any significant illness.
Subjects with heart problems.
Subjects who have had a cold or chest infection 2-4 weeks prior to the study.
Subjects who take medication for their asthma, or other conditions, not compatible with the study.